bicistronic construct; fluorescence-activated cell sorting; angiogenesis; gene expression TARGETED GENE INACTIVATION by tissue-specific and inducible expression of the Cre recombinase of bacteriophage P1 (3, 15 ) is a powerful tool for examining the role of individual genes in biological processes (11, 13) . The Cre/lox system can be used to control gene activation or inactivation in a temporally and/or spatially specified manner, thereby facilitating the determination of gene function. The use of green fluorescent protein (12) or the fluorescence-activated cell sorting (FACS)-optimized analog enhanced green fluorescent protein (eGFP) (2) , as markers of gene expression (4) , has enabled the monitoring of promoter activity and cell lineage in vivo (17) . The combination of these techniques extends their particular applications in the context of the study of specific cell lineages within a heterogenous tissue. For example, myocytes may constitute a modest percentage of the total cells in a particular tissue, complicating the determination of gene expression in this cell type.
Many genes that are restricted to smooth muscle in adult animals are transiently expressed in other tissues during development (5, 7, 14, 16) , complicating the use of the promoters of these genes for the construction of tissue-restricted transgenes. In this regard, the smooth muscle myosin heavy chain (smMHC) promoter specifies smooth muscle-restricted gene expression during development and in the adult mouse (7, 8) , and this promoter has recently been used for the generation of mice expressing Cre recombinase in smooth muscle tissues (14) . Here we report the use of the smMHC promoter in the production of transgenic mice that express a bicistronic transgene consisting of Cre recombinase and eGFP in a smooth muscle-restricted manner. The mice should be useful for the generation of smooth muscle-specific knockout mice, in which the expressed eGFP will provide an indication of the extent of Cre recombinase expression in live cells. Moreover, disaggregated cells from these mice can be easily sorted and used for the determination of gene expression in vascular and nonvascular smooth muscle.
METHODS
Generation of smMHC/Cre/eGFP transgenic mice. The transgene was constructed using the mouse smMHC promoter (kindly provided by Dr. G. K. Owens, University of Virginia), Cre recombinase (Invitrogen, Carlsbad, CA), and eGFP (Clontech, Palo Alto, CA) coding sequences as shown in Fig. 1 . An approximately 16-kb smMHC promoter fragment including intron 1, previously shown to direct expression of a Article published online before print. See web site for date of publication (http://physiolgenomics.physiology.org).
lacZ reporter gene to smooth muscle tissues (8) , was used to drive Cre recombinase and eGFP expression. An internal ribosome entry site (IRES) of the encephalomyocarditis virus was added upstream of the eGFP gene to permit the translation of two open reading frames for Cre and eGFP from one mRNA (6) . The transgene was purified using a Qiagen kit and injected into fertilized mouse eggs by standard pronuclear microinjection techniques. Two transgenic founder lines were generated and bred to C57/B6 mice. Mice were genotyped by PCR with genomic DNA purified from either tail clips or yolk sac (embryonic mice), using Cre-specific primers (primer 1, 5Ј-CCA ATT TAC TGA CCG TAC ACC-3Ј; primer 2, 5Ј-GTT TCA CTA TCC AGG TTA CGG-3Ј), or by Southern blotting EcoRI digested genomic DNA, using a probe from the coding region of Cre recombinase. Two founder lines were developed (SMCG2 and SMCG3).
Microscopy, cell dissociation, and sorting. eGFP fluorescence in cryosections and mouse embryos was visualized using epifluorescence microscopy. To determine Cre recombinase activity, male smMHC/Cre/eGFP mice from one founder line (SMCG2) were mated with female R26R mice (9) obtained from Jackson Laboratories. In this line a floxed stop element followed by the lacZ gene has been knocked into the ROSA26 locus; since the floxed stop element is excised only in tissue in which Cre recombinase is expressed, expression of ␤-galactosidase serves as a marker of Cre expression. Embryos and tissues were collected in PBS, fixed in 4% paraformaldehyde, washed with PBS, and stained with 5-bromo-4-chloro-3-indolyl-D-galactopyranoside (X-gal) at room temperature overnight. For immunocytochemistry, tissues were fixed in neutral buffered formalin overnight, embedded and sectioned, and sections digested with pronase for 20 min at 37°C before immunostaining. Immunostaining with primary antibodies was followed by a biotinylated secondary antibody, labeling with streptavidin, and detection by 3-amino-9-ethylcarbozole. Nuclei were counterstained with hematoxylin. Mouse anti-Cre recombinase monoclonal antibody (catalog no. MAB 3120) and rabbit anti-GFP polyclonal antibody (catalog no. AB 3080) were purchased from Chemicon. Dilutions were 1:50 (anti-Cre) and 1:30 (anti-GFP). Nonimmune rabbit serum or mouse ascites fluid served as negative control to verify the specificity of the results.
Single cells were prepared by dissection of the media of the aorta and the muscularis of the urinary bladder free from overlying tissues and enzymatic disaggregation of smooth muscle cells as previously described (1, 18) . Cells were visualized on an inverted microscope (model TE300, Nikon) using wide-field epifluorescence or laser-scanning confocal microscopy (Radiance 2000, Bio-Rad). Pooled segments from two mouse aortas were enzymatically disaggregated as above, filtered through 500 m Nytex mesh, and sorted. Enzymatically disaggregated aortic myocytes were sorted using a dual-laser fluorescence-activated cell sorter (EPICS, Coulter Electronics). Flow cytometry was done with 200 mW of 488-nm excitation.
RESULTS
Expression of eGFP in smMHC/Cre/eGFP mice. We bred two transgenic founder lines of smMHC/Cre/ eGFP mice: SM2
Cre/GFP and SM3 Cre/GFP , which we refer to as lines SMCG2 and SMCG3. Southern blot analysis indicated a single integration site in both lines; SMCG2 mice displayed a higher transgene copy number, as indicated by comparison of the Southern blots under equal loading conditions (Fig. 1) . SMCG2 hemizyotic mice were crossed to yield homozygotes, which could be distinguished from hemizygotes by the intensity of the hybridized band. SMCG2 transgenic mice were viable as hemizygotes and homozygotes; however, it was observed that homozygotes (SM Cre/GFP,Cre/GFP ) had smaller litter sizes and a higher incidence of perinatal mortality. As hemizygotes from both lines displayed intense eGFP fluorescence (see below), both lines were maintained as hemizygotes, and the SMCG2 line was chosen for rigorous analysis. As shown in Fig.  2 , adult SMCG2 hemizygotic mice displayed intense GFP fluorescence restricted to vascular and nonvascular smooth muscle. Fluorescence was easily observed in newborn pups, and animals were rapidly genotyped by examination of a small section of ear or tail under a dissecting microscope for vascular fluorescence (Fig.  2B) . Slight, diffuse fluorescence was observed in the atria at day 10.5, similar to previous reports for lacZ expression (14) . More intense, localized eGFP fluorescence could be detected in the aorta and major airways at 12.5 days post-coitus (dpc), whereas smooth muscle fluorescence was prominent at 16.5 dpc in the intestine. An example of fluorescence in the lung of a 16.5 dpc embryo is shown in Fig. 2. A significant advantage and major rationale for the generation of smMHC/Cre/eGFP mice is the ability to identify individual myocytes in complex tissues for physiological or gene expression studies. Accordingly, the fluorescence of individual myocytes within the smooth muscle matrix and of dissociated myocytes was examined. Individual myocytes were easily observed in cryosections of smooth muscle tissue (not shown), and single myocytes were dissociated from vascular and nonvascular smooth muscle tissues to determine the effect on eGFP expression. As shown in Fig. 3 , individual cells from these mice display intense cytosolic fluorescence after enzymatic digestion. In confocal images fluorescence was observed diffusely throughout the cytoplasm, and cells could be easily separated from non- smooth muscle cells by FACS. To establish the feasibility of separation of myocytes from other cell types by FACS, two separate sorts were conducted of dissociated aortas from 3-wk-old mice. In both experiments fluorescent myocytes were readily separated from other cell types, yielding a homogenous population of fluorescent cells. Sorted cells constituted 14% of the total cell suspension from whole aorta.
Expression of Cre recombinase. To determine the expression of Cre recombinase, SM2
Cre/GFP mice were crossed with R26R mice, in which a stop element flanked by loxP sequences upstream of the lacZ coding sequence has been knocked into the ROSA26 locus (9). F1 offspring were genotyped for both alleles and double heterozygotes crossed to yield SM2
Cre/GFP,R26R mice for analysis. SM2
Cre/GFP,R26R displayed prominent lacZ staining in smooth muscle tissues, whereas no staining was observed in SM2
Cre/GFP mice. LacZ expression was observed as early as 12.5 dpc, similar to previous findings (14) . In some experiments, tissues were stained for lacZ expression, and fluorescence was visualized in the same tissues. As shown in Fig. 4 , A and B, there was strong overlap between Cre-mediated ␤-galactosidase expression and eGFP fluorescence, verifying the use of fluorescence as a marker for conditional gene recombination. To further document the concordant expression of Cre recombinase and eGFP at a cellular level, tissues from wild-type and transgenic mice were sectioned, and immunostaining was performed using anti-GFP and anti-Cre recombinase antibodies. As shown in Fig. 4C , eGFP immunodetection demonstrated diffuse cytosolic staining confined to smooth muscle cells; Cre expression was similarly confined to smooth muscle cells, but showed the expected nuclear localization in myocytes. The smooth muscle-specific nature of expression was further confirmed by the observation of positive vascular myocytes within cardiac (Fig. 4C) and skeletal (not shown) muscle. Vascular smooth muscle expression of Cre and eGFP was observed in all tissues, including renal arteries and arterioles (Fig. 4C) . Similarly, expression of the transgene was observed in adult mice in all nonvascular smooth muscle, including smooth muscle layers of the male and female reproductive tracts (not shown) and the circular and longitudinal muscle of the gastrointestinal tract (Cre recombinase expression shown in Fig. 4C ).
DISCUSSION
Smooth muscle cells reside within a complex matrix that includes closely related mesenchymal cells such as fibroblasts, glia, neurons, and often closely adherent endothelial cells. The separation of myocytes from the surrounding cellular environment to isolate musclespecific adaptations or disease responses, particularly in the vasculature of the mouse, is therefore quite challenging. The ability to accurately examine shifts in gene expression in smooth muscle such as are likely to occur in vascular disease would be substantially improved by the ability to separate myocytes by FACS or microdissection methods utilizing markers of cell lineage. To address this difficulty, we have engineered a transgenic mouse expressing eGFP and Cre recombinase under the control of the smMHC gene promoter. smMHC appears to be the most smooth muscle-restricted gene identified to date (10) and has been shown to direct expression of a reporter gene to smooth muscle (8) . Although full promoter activity requires a large gene fragment including the first intron of the smMHC gene (ϳ16 kb), the restriction of the transgene to smooth muscle tissue was deemed essential for the utility of this transgenic line. The specificity of this promoter has previously been exploited to develop a mouse expressing smooth muscle-restricted Cre recombinase (14) . By combining eGFP with Cre recombinase on a bicistronic construct, smMHC/Cre/eGFP mice should be useful tools for conditional gene inactivation or activation, as well as the analysis of gene expression in myocytes by fluorescence-based cell separation techniques. The transgenic lines reported here express the bicistronic transgene beginning in late embryonic development in a tissue-restricted fashion, although early fluorescence was detected in the atrium between days 10.5 and 12.5 dpc, consistent with previous reports (14) . Fluorescence expression also provides a rapid and convenient method of genotyping by observation of a small segment of tissue for vascular fluorescence. Finally, we found that eGFP fluorescence and Cre expression are well linked, providing a convenient in vivo marker for Cre-mediated genetic manipulations.
